New drug strategy aims to shrink tumors before surgery in advanced lung cancer
NCT ID NCT05740943
Summary
This study is testing whether giving the drug lorlatinib before surgery or radiation helps people with stage III non-small cell lung cancer that has a specific genetic change (ALK fusion). About 48 participants will take lorlatinib for three cycles. Doctors will then check if the tumor has shrunk enough for surgery or radiation, followed by possible additional treatment. The main goal is to see if the drug can completely eliminate the cancer cells in the removed tissue.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SURGERY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510080, China
-
Guangzhou Twelfth People's Hospital
Guangzhou, Guangdong, China
-
Peking Union Medical College Hospital
Beijin, Beijin, 100730, China
-
The Second Xiangya Hospital of Central South University
Changsha, Hunan, 410011, China
Conditions
Explore the condition pages connected to this study.